InterMune Reports Third Quarter 2013 Financial Results And Business Highlights


8th Consecutive of Esbriet Revenue Growth —
BRISBANE, Calif., Oct. 30, /PRNewswire/ — , Inc. (NASDAQ: ITMN) today announced from operations for the quarter and nine months ended September 30, 2013, and recent .   
InterMune reported Esbriet® (pirfenidone) revenue in the third quarter of 2013 of $ 19.7 million, compared with $ 7.5 million of Esbriet revenue in the third quarter of 2012, an increase of 163 percent.  Sequentially, Esbriet revenue in the third quarter of 2013 increased 37 percent from $ 14.4 million in the second quarter of 2013.  Esbriet is InterMune’s product marketed in Europe and Canada for the treatment of adult patients with mild to moderate idiopathic pulmonary fibrosis (IPF).
Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, “Notably, Esbriet revenue growth in the third quarter came from both new country launches and growth in countries where the product has been available.  During the quarter we launched Esbriet in Italy and the UK, two of the five largest countries in Europe, as well as in Finland and Ireland.  Esbriet revenue grew in the third quarter in countries where Esbriet had previously been launched, with Germany, France, the mid-sized European countries and Canada all reporting sequential double-digit growth.  We are particularly pleased to report strong growth in Germany during the third quarter, where we see continued market penetration and improved persistence after two full years of marketing Esbriet in that country.”  
“Regarding the U.S. market, we remain on track to report top-line results from the confirmatory Phase 3 ASCEND study of Esbriet in the second quarter of 2014,” Mr. Welch added.  
Recent Business and Clinical Development Highlights
•    In…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS